The Coexistence of Genetic Mutations in Thyroid Carcinoma Predicts Histopathological Factors Associated With a Poor Prognosis: A Systematic Review and Network Meta-Analysis
Ling Zhao,Lin Wang,Xiaomeng Jia,Xiaodong Hu,Ping Pang,Sitong Zhao,Yajing Wang,Jing Wang,Yingshi Zhang,Zhaohui Lyu
DOI: https://doi.org/10.3389/fonc.2020.540238
IF: 4.7
2020-11-03
Frontiers in Oncology
Abstract:<span><strong>Purpose:</strong> Genetic mutations may play an important role in the progression and invasion of thyroid carcinoma (TC), and their coexistence may result in mutational synergy. The presence of the <i>BRAF<sup>V600E</sup></i> mutation, as well as mutations affecting the <i>TERT</i> promoter, <i>RAS</i>, <i>CHEK2</i> and <i>RET/PTC</i>, may all have an impact on prognosis. The aim of this study was to explore whether synergy between the coexistent mutations predicts histopathological prognostic factors that influence disease outcome.<strong>Methods:</strong> A comprehensive literature search of PubMed, Embase and the Cochrane Library, from their inception until January 2020. Primary outcomes included: disease stage, lymph node metastasis, extrathyroidal extension and distant metastasis; while, secondary outcomes included: tumor recurrence, mortality, invasion of thyroid capsule, multiplicity, presented as an odds ratio (OR) with 95% credible intervals (CrI).<strong>Results:</strong> 27 publications (comprising 9 active intervention arms), involving 8,388 TC patients, were selected. Network meta-analytic estimates of active interventions contrasted with other active interventions, with random effects, were calculated. In terms of outcomes focus on overall TC, <i>BRAF<sup>V600E</sup></i> + <i>TERT</i> co-mutation ranked highest for diseases stage (OR = 5.74, 95% CrI: 3.09–10.66), as well as lymph node metastasis, extrathyroidal extension (5.74, 4.06–8.10), tumor recurrence (7.21, 3.59–14.47), and invasion of the thyroid capsule (3.11, 1.95–4.95). <i>BRAF<sup>V600E</sup></i> + <i>TERT</i> co-mutation ranked secondary in distant metastasis, mortality, and multiplicity that ranked highest was <i>TERT</i>+<i>RAS</i> or <i>RAS</i>. When we were limited to the study of patients with papillary TC (PTC), <i>BRAF<sup>V600E</sup></i> + TERT always ranked highest for primary outcomes: disease stage (6.39, 3.13–13.04), lymph node metastasis, extrathyroidal extension (5.80,3.89–8.64) and distant metastasis (7.33, 3.00–17.89), while <i>BRAF<sup>V600E</sup></i> + <i>TERT</i> again ranked highest in secondary outcomes: tumor recurrence (7.23,3.37–15.51), mortality (9.26, 3.02–28.42), invasion of thyroid capsule (3.20,2.01–5.11), and multiplicity.<strong>Conclusions:</strong> In this molecular marker mutation-based systematic review and network meta-analysis, we found that coexistent <i>BRAF<sup>V600E</sup></i> + <i>TERT</i> genetic co-mutations predicted poor histopathological prognosis, including progression, invasion, and metastasis, especially in PTC. For the overall TC, the <i>BRAF<sup>V600E</sup></i> + <i>TERT</i> + <i>RAS</i> triple mutations may have a greater impact on the prognosis, and further research should related to potentially important features. This study is registered with PROSPERO, number CRD42019143242.</span>
oncology